|Figure 1. Current and emerging applications using hMSCs as a critical raw material.|
Human mesenchymal stem/stromal cells (hMSCs) are a critical starting material in a growing variety of established and emerging applications spanning the Regenerative Medicine space (Fig1). Their unique balance of functional bioactive attributes, expansion potential, and established safety profile have resulted in a steady increase in both scientific publications and a parallel increased presence in clinical applications over the past 10+ years. Specific to scientific publications, from 2011 to 2015 there were over 17,000 MSC related publications, with over 50% pertaining to human MSC use. This trend has continued with over 9,600 MSC related publications in 2016-2017 and with over 5,000 articles using human hMSCs.
We are excited that over the past 4 years RoosterBio’s core technology, hMSC cell banks and associated Bioprocess Media Systems have been a used in an increasing number of these peer reviewed scientific publications or what we affectionally refer to as our customer’s “brainy stuff”. The initial articles using RoosterBio technology were published in Biomacromolecules and Cytotherapy in the 2nd half of 2015; less than 2 years from when our first products left RoosterBio’s doors. During 2016 and 2017, RoosterBio products have appeared in leading academic journals such as PNAS (twice), Biomaterials, Stem Cells and Translational Medicine, American Journal of Respiratory and Critical Care Medicine, and Nucleic Acids Research.
Figure 2: Key Metrics of Publications using RoosterBio products.
In addition to a presence in these high-profile publications, RoosterBio's hMSC manufacturing-focused products, have had a steady yearly increase in overall total peer reviewed articles in print (Fig. 2). In 2018 to date a total of 35 articles have included RBI products, surpassing 2017’s total and doubling 2016’s output. In addition to total publications, we have tracked articles using a few key metrics – Journal’s Impact Factor (IF), an index of citations per publication, and studies which contain an in vivo, or animal model component (Fig 2). With respect to IF, articles using RBI product have had an increase in average IF from 4.4 in 2016 to 5.2 in 2018 and total number of publications with an IF >4 from 5 articles in 2015 to 17 to date in 2018, which is almost half of the total articles this year. Original research articles with an in vivo component have had similar increases, from 2 articles (12%) in 2015 to 10 articles (28%) so far in 2018.
The breadth of topics included in these publications is as diverse as current applications across the hMSC Regenerative Medicine space – and is called out in our databaseof current RoosterBio product publications. As frequency of publications increases, we will highlight some of these – starting with some recent exciting work being reported across the industry:
IFN-γ and TNF-α Pre-licensing Protects Mesenchymal Stromal Cells from the Pro-inflammatory Effects of Palmitate. Boland L, Burand AJ, Brown AJ, Boyt D, Lira VA, Ankrum JA. Mol Ther. 2018.
Deciphering the role of substrate stiffness in enhancing the internalization efficiency of plasmid DNA in stem cells using lipid-based nanocarriers. Modaresi S, Pacelli S, Whitlow J, Paul A. Nanoscale. 2018.
Acoustophoretic printing. Foresti D, Kroll KT, Amissah R, Sillani F, Homan KA, Poulikakos D, Lewis JA. Sci Adv. 2018.
3D printed biofunctionalized scaffolds for microfracture repair of cartilage defects. Guo T, Noshin M, Baker HB, Taskoy E, Meredith SJ, Tang Q, Ringel JP, Lerman MJ, Chen Y, Packer JD, Fisher JP. Biomaterials. 2018.
Mesenchymal stem cell-derived extracellular vesicles attenuate pulmonary vascular permeability and lung injury induced by hemorrhagic shock and trauma. Potter DR, Miyazawa BY, Gibb SL, Deng X, Togaratti PP, Croze RH, Srivastava AK, Trivedi A, Matthay M, Holcomb JB, Schreiber MA, Pati S. J Trauma Acute Care Surg. 2018.
If you are interested in having a conversation about how RoosterBio can shorten your gaps between experiments and accelerate your time to publication, contact us at firstname.lastname@example.org.